<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Neuphoria Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/neuphoria-therapeutics-inc</link>
<description>Latest news and press releases for Neuphoria Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 08 Dec 2025 13:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/neuphoria-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a18b78dffbe2df10957c.webp</url>
<title>Neuphoria Therapeutics Inc</title>
<link>https://6ix.com/company/neuphoria-therapeutics-inc</link>
</image>
<item>
<title>Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria’s Director Nominees</title>
<link>https://6ix.com/company/neuphoria-therapeutics-inc/news/leading-proxy-advisory-firm-iss-130000014</link>
<guid isPermaLink="true">https://6ix.com/company/neuphoria-therapeutics-inc/news/leading-proxy-advisory-firm-iss-130000014</guid>
<pubDate>Mon, 08 Dec 2025 13:00:00 GMT</pubDate>
<description>Company Urges Shareholders to Follow ISS’ Recommendation and Vote the WHITE Proxy Card BURLINGTON, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today announced that Institutional Shareholders Services (“ISS”), a leading independent proxy advisory firm, has issued a repo</description>
</item>
<item>
<title>Neuphoria Responds to Lynx1’s Revised Indication of Interest at a Reduced Price and Premium</title>
<link>https://6ix.com/company/neuphoria-therapeutics-inc/news/neuphoria-responds-lynx1-revised-indication-130000660</link>
<guid isPermaLink="true">https://6ix.com/company/neuphoria-therapeutics-inc/news/neuphoria-responds-lynx1-revised-indication-130000660</guid>
<pubDate>Thu, 04 Dec 2025 13:00:00 GMT</pubDate>
<description>Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest Urges Stockholders to Vote “FOR” BOTH of Neuphoria’s Nominees on the WHITE Proxy Card BURLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today</description>
</item>
<item>
<title>Lynx1 Sends Open Letter to Fellow Neuphoria Shareholders</title>
<link>https://6ix.com/company/neuphoria-therapeutics-inc/news/lynx1-sends-open-letter-to-fellow-neuphoria-shareholders</link>
<guid isPermaLink="true">https://6ix.com/company/neuphoria-therapeutics-inc/news/lynx1-sends-open-letter-to-fellow-neuphoria-shareholders</guid>
<pubDate>Tue, 02 Dec 2025 23:48:00 GMT</pubDate>
<description>Lynx1 Master Fund LP (together with its affiliates, "Lynx1"), the beneficial owner of 875,328 shares of common stock, par value $0.00001 per share ("Common Stock"), of Neuphoria Therapeutics Inc., a Delaware corporation ("Neuphoria" or the "Company"), today sent an open letter to the shareholders of Neuphoria.</description>
</item>
<item>
<title>Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions</title>
<link>https://6ix.com/company/neuphoria-therapeutics-inc/news/neuphoria-provides-facts-exposes-false-130000296</link>
<guid isPermaLink="true">https://6ix.com/company/neuphoria-therapeutics-inc/news/neuphoria-provides-facts-exposes-false-130000296</guid>
<pubDate>Mon, 01 Dec 2025 13:00:00 GMT</pubDate>
<description>BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following statements to address what Neuphoria strongly believes is a campaign from Lynx1 Master Fund LP (“Lynx1”) full of deception and distraction to deflect attention from its own limitations a</description>
</item>
<item>
<title>Neuphoria Therapeutics Inc. Sends Letter to Stockholders</title>
<link>https://6ix.com/company/neuphoria-therapeutics-inc/news/neuphoria-therapeutics-inc-sends-letter-130000864</link>
<guid isPermaLink="true">https://6ix.com/company/neuphoria-therapeutics-inc/news/neuphoria-therapeutics-inc-sends-letter-130000864</guid>
<pubDate>Mon, 24 Nov 2025 13:00:00 GMT</pubDate>
<description>Files Definitive Proxy Statement for 2025 Annual Meeting of Stockholders Urges Stockholders to Vote “FOR” BOTH Neuphoria Therapeutics Nominees on WHITE Proxy Card BURLINGTON, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued a letter to its stockholders regarding Neuphoria’s 2</description>
</item>
<item>
<title>Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value</title>
<link>https://6ix.com/company/neuphoria-therapeutics-inc/news/neuphoria-announces-initiation-strategic-review-120000143</link>
<guid isPermaLink="true">https://6ix.com/company/neuphoria-therapeutics-inc/news/neuphoria-announces-initiation-strategic-review-120000143</guid>
<pubDate>Tue, 11 Nov 2025 12:00:00 GMT</pubDate>
<description>Confirms Receipt of Unsolicited Indication of Interest and Director Nominations from Lynx1 Master Fund LP No Stockholder Action Required at This Time BURLINGTON, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (Nasdaq: NEUP), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced, as previously disclosed, the initiation of a review of strategic alternatives to advance the Company’s</description>
</item>
<item>
<title>Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process</title>
<link>https://6ix.com/company/neuphoria-therapeutics-inc/news/neuphoria-therapeutics-adopts-limited-duration-202900274</link>
<guid isPermaLink="true">https://6ix.com/company/neuphoria-therapeutics-inc/news/neuphoria-therapeutics-adopts-limited-duration-202900274</guid>
<pubDate>Mon, 27 Oct 2025 20:29:00 GMT</pubDate>
<description>BURLINGTON, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (Nasdaq: NEUP), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced that its Board of Directors (the “Board”) has determined to adopt a limited-duration stockholder rights plan (the “Rights Plan”), effective immediately. The Board adopted the Rights Plan in response to significant and rapid accumulations of the Company’</description>
</item>
<item>
<title>Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder</title>
<link>https://6ix.com/company/neuphoria-therapeutics-inc/news/neuphoria-therapeutics-provides-affirm-1-201500619</link>
<guid isPermaLink="true">https://6ix.com/company/neuphoria-therapeutics-inc/news/neuphoria-therapeutics-provides-affirm-1-201500619</guid>
<pubDate>Mon, 20 Oct 2025 20:15:00 GMT</pubDate>
<description>AFFIRM-1 trial did not meet primary endpoint or secondary endpoints Company to conduct strategic review of portfolio and business operations BURLINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced that the AFFIRM-1 Phase 3 trial of BNC210 for the acute treatment of social anxiety disorder (SAD) did not meet</description>
</item>
<item>
<title>Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates</title>
<link>https://6ix.com/company/neuphoria-therapeutics-inc/news/neuphoria-provides-fiscal-end-2025-205400069</link>
<guid isPermaLink="true">https://6ix.com/company/neuphoria-therapeutics-inc/news/neuphoria-provides-fiscal-end-2025-205400069</guid>
<pubDate>Mon, 29 Sep 2025 20:54:00 GMT</pubDate>
<description>Last patient last visit (LPLV) milestone in AFFIRM-1 Phase 3 trial of BNC-210 in social anxiety disorder (SAD) achieved; topline readout anticipated in early Q4 2025 Cash runway extended through fiscal Q2 2027 BURLINGTON, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today reported its financial results for its fiscal year e</description>
</item>
<item>
<title>Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)</title>
<link>https://6ix.com/company/neuphoria-therapeutics-inc/news/neuphoria-therapeutics-completes-target-enrollment-110000622</link>
<guid isPermaLink="true">https://6ix.com/company/neuphoria-therapeutics-inc/news/neuphoria-therapeutics-completes-target-enrollment-110000622</guid>
<pubDate>Thu, 04 Sep 2025 11:00:00 GMT</pubDate>
<description>Topline data anticipated in early Q4 2025BURLINGTON, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced the achievement of target enrollment of 332 participants in the AFFIRM-1 Phase 3 trial evaluating lead candidate BNC-210 as a first-in-class, acute, “as needed”, fast-acting treatment for social anxiety disorder</description>
</item>
<item>
<title>Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/neuphoria-therapeutics-inc/news/neuphoria-therapeutics-present-h-c-200500823</link>
<guid isPermaLink="true">https://6ix.com/company/neuphoria-therapeutics-inc/news/neuphoria-therapeutics-present-h-c-200500823</guid>
<pubDate>Thu, 28 Aug 2025 20:05:00 GMT</pubDate>
<description>BURLINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced that Spyros Papapetropoulos, M.D., Ph.D., President and CEO, will be presenting at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 in New York, NY. The presentation will be available on demand here starting o</description>
</item>
<item>
<title>Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting</title>
<link>https://6ix.com/company/neuphoria-therapeutics-inc/news/neuphoria-present-american-society-clinical-201000118</link>
<guid isPermaLink="true">https://6ix.com/company/neuphoria-therapeutics-inc/news/neuphoria-present-american-society-clinical-201000118</guid>
<pubDate>Tue, 27 May 2025 20:10:00 GMT</pubDate>
<description>BURLINGTON, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced an upcoming presentation at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting. Presentation details: Title: Pharmacokinetic/Pharmacodynamic Analysis of the BNC210 Attune Phase 2b Dataset Enables Dose Selection for Planned Pha</description>
</item>
<item>
<title>Neuphoria Provides First Quarter 2025 Business Updates</title>
<link>https://6ix.com/company/neuphoria-therapeutics-inc/news/neuphoria-provides-first-quarter-2025-202200672</link>
<guid isPermaLink="true">https://6ix.com/company/neuphoria-therapeutics-inc/news/neuphoria-provides-first-quarter-2025-202200672</guid>
<pubDate>Tue, 20 May 2025 20:22:00 GMT</pubDate>
<description>Cash runway into Q3 2026AFFIRM-1 Phase 3 clinical trial of BNC-210 in social anxiety disorder on track for topline readout in Q3 2025α7 nicotinic acetylcholine receptor PAM MK-1167 partnered with Merck and in Phase 2 clinical trial in Alzheimer’s BURLINGTON, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today provides business</description>
</item>
<item>
<title>Neuphoria Provides a Review of 2024 and Highlights 2025 Plans</title>
<link>https://6ix.com/company/neuphoria-therapeutics-inc/news/neuphoria-provides-review-2024-highlights-120000803</link>
<guid isPermaLink="true">https://6ix.com/company/neuphoria-therapeutics-inc/news/neuphoria-provides-review-2024-highlights-120000803</guid>
<pubDate>Tue, 15 Apr 2025 12:00:00 GMT</pubDate>
<description>Initiation by Merck of a Phase 2 trial in Alzheimer’s disease with partnered α7 nicotinic acetylcholine receptor PAM MK-1167 highlights company’s pipeline diversification beyond BNC210US $15M milestone payment from Merck extends company’s cash runway to Q3 2026Phase 3 AFFIRM-1 trial of BNC210 in social anxiety disorder (SAD) is progressing as planned with topline readout anticipated in Q3 2025A Phase 2b dose ranging study with a lower dose of BNC210 in post-traumatic stress disorder (PTSD) is pl</description>
</item>
<item>
<title>Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025</title>
<link>https://6ix.com/company/neuphoria-therapeutics-inc/news/neuphoria-therapeutics-ring-nasdaq-opening-123000156</link>
<guid isPermaLink="true">https://6ix.com/company/neuphoria-therapeutics-inc/news/neuphoria-therapeutics-ring-nasdaq-opening-123000156</guid>
<pubDate>Mon, 03 Mar 2025 12:30:00 GMT</pubDate>
<description>BURLINGTON, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (Neuphoria or Company), ”), a clinical-stage biotechnology developing impactful treatments for neuropsychiatric disorders, bringing new hope and tangible improvements to patients’ lives, announced today that it will ring the Opening Bell at the Nasdaq MarketSite in Times Square, New York City on Monday, March 3rd, 2025. Spyros Papapetropoulos MD, PhD, President and Chief Executive Officer will be joi</description>
</item>
<item>
<title>Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck</title>
<link>https://6ix.com/company/neuphoria-therapeutics-inc/news/neuphoria-therapeutics-inc-to-receive-dollar15m-milestone-payment-from-merck</link>
<guid isPermaLink="true">https://6ix.com/company/neuphoria-therapeutics-inc/news/neuphoria-therapeutics-inc-to-receive-dollar15m-milestone-payment-from-merck</guid>
<pubDate>Wed, 12 Feb 2025 05:00:00 GMT</pubDate>
<description>Milestone payment triggered by the initiation of a Phase 2 clinical trial in Alzheimer’s disease with MK-1167, an α7 nicotinic acetylcholine receptor positive</description>
</item>
<item>
<title>Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq</title>
<link>https://6ix.com/company/neuphoria-therapeutics-inc/news/neuphoria-completes-re-domiciliation-and-successor-listing-on-nasdaq</link>
<guid isPermaLink="true">https://6ix.com/company/neuphoria-therapeutics-inc/news/neuphoria-completes-re-domiciliation-and-successor-listing-on-nasdaq</guid>
<pubDate>Mon, 23 Dec 2024 05:00:00 GMT</pubDate>
<description>BURLINGTON, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”) is pleased to announce that its</description>
</item>
<item>
<title>Bionomics Announces Supreme Court of New South Wales Approves Bionomics’ Re-Domiciliation</title>
<link>https://6ix.com/company/neuphoria-therapeutics-inc/news/bionomics-announces-supreme-court-of-new-south-wales-approves-bionomics-re-domiciliation</link>
<guid isPermaLink="true">https://6ix.com/company/neuphoria-therapeutics-inc/news/bionomics-announces-supreme-court-of-new-south-wales-approves-bionomics-re-domiciliation</guid>
<pubDate>Mon, 16 Dec 2024 05:00:00 GMT</pubDate>
<description>ADELAIDE, Australia, and CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company) is pleased to announce</description>
</item>
<item>
<title>Results of Scheme Meeting</title>
<link>https://6ix.com/company/neuphoria-therapeutics-inc/news/results-of-scheme-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/neuphoria-therapeutics-inc/news/results-of-scheme-meeting</guid>
<pubDate>Thu, 12 Dec 2024 05:00:00 GMT</pubDate>
<description>ADELAIDE, Australia and CAMBRIDGE, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (“Bionomics” or the “Company”) is pleased to</description>
</item>
<item>
<title>Bionomics Publishes the Positive Results from the Phase 2 ATTUNE Study of BNC210 in Patients with Post-Traumatic Stress Disorder in NEJM Evidence</title>
<link>https://6ix.com/company/neuphoria-therapeutics-inc/news/bionomics-publishes-the-positive-results-from-the-phase-2-attune-study-of-bnc210-in-patients-with-post-traumatic-stress-disorder-in-nejm-evidence</link>
<guid isPermaLink="true">https://6ix.com/company/neuphoria-therapeutics-inc/news/bionomics-publishes-the-positive-results-from-the-phase-2-attune-study-of-bnc210-in-patients-with-post-traumatic-stress-disorder-in-nejm-evidence</guid>
<pubDate>Mon, 09 Dec 2024 05:00:00 GMT</pubDate>
<description>BNC210 improved PTSD symptom severity at Week 12 with efficacy observed as early as Week 4Company plans to initiate a Phase 3 study of BNC210 in PTSD in H2</description>
</item>
</channel>
</rss>